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Abstract
Background and aims: Increased expression of Chromosome Region Maintenance (CRM-1)/exportin-1 (XPO-1)
has been correlated with poor prognosis in several aggressive tumors, making it an interesting therapeutic target.
Selective Inhibitor of Nuclear Export (SINE) compounds bind to XPO-1 and block its ability to export cargo proteins.
Here, we investigated the effects of a new class of SINE compounds in models of prostate cancer.
Material and methods: We evaluated the expression of XPO-1 in human prostate cancer tissues and cell lines.
Next, six SINE (KPT-127, KPT-185, KPT-205, KPT-225, KPT-251 and KPT-330) compounds having different potency
with broad-spectrum, tumor-selective cytotoxicity, tolerability and pharmacokinetic profiles were tested in a panel
of prostate cancer cells representing distinct differentiation/progression states of disease and genotypes. Two SINE
candidates for clinical trials (KPT-251 and KPT-330) were also tested in vivo in three cell models of aggressive prostate
cancer engrafted in male nude mice.
Results and conclusions: XPO-1 is overexpressed in prostate cancer compared to normal or hyperplastic tissues.
Increased XPO-1 expression, mainly in the nuclear compartment, was associated with increased Gleason score and bone
metastatic potential supporting the use of SINEs in advanced prostate cancer. SINE compounds inhibited proliferation
and promoted apoptosis of tumor cells, but did not affect immortalized non-transformed prostate epithelial cells. Nuclei
from SINE treated cells showed increased protein localization of XPO-1, survivin and cyclin D1 followed by degradation
of these proteins leading to cell cycle arrest and apoptosis. Oral administration of KPT-251 and KPT-330 in PC3, DU145
and 22rv1 tumor-bearing nude mice reduced tumor cell proliferation, angiogenesis and induced apoptosis. Our results
provide supportive evidence for the therapeutic use of SINE compounds in advanced/castration resistant prostate
cancers and warrants further clinical investigation.
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Background
Prostate cancer (PCa) is the second leading cause of can-
cer mortality in males >40 years of age in the USA and
the third most common cause of cancer-related mortal-
ity in males [1]. PCa is generally a slow developing can-
cer, and 5- and 10-year relative survival rates of early
stage PCa are 99 and 95 %, respectively [2]. Although
hormone therapy is initially very effective, almost all tu-
mors relapse to a hormone refractory stage. In the past,
it was presumed that the expression of the androgen re-
ceptor (AR) is lost in the cells of advanced, hormone-
refractory tumors but AR is rarely lost in human PCa
specimens in vivo, even in those of CRPC [3]. Not only
that AR is not lost, but it is transcriptionally active in
the majority of recurrent CRPC [4]. There is experimen-
tal evidence that the Akt, mTOR and glycogen synthase
kinase-3 (GSK-3β) pathways are involved in AR signaling
[5, 6]. GSK-3β binds to the AR, forming a complex in
the cytoplasm that are then imported into the nucleus
upon androgenic stimulation. Inhibition of GSK-3β by
activation of Akt/mTOR pathways results in increased
nuclear export of AR and this export can be abrogated
by the inhibition of XPO-1. GSK-3β/XPO-1 activity also
regulates the levels of several nuclear and cytoplasmic
proteins including survivin [7, 8] and cyclin D1 [8],
which modulate cell division and apoptosis. Advanced
castration resistant prostate cancer (CRPC) tumors are
characterized by the activation of PI3K/AKT [9, 10].
One of the major effects of the activation of this pathway
is XPO-1 dependent nuclear export of the tumor sup-
pressor protein (TSP) FOXO into the nucleus, thus abol-
ishing its activity [11]. Normally, low levels of FOXO
protein are found in the cytoplasm. Shortly after SINE
treatment, FOXO begins to accumulate in the nucleus
where it binds to DNA and induces gene transcription
that results in cancer cell death [12, 13].
Cancer cells utilize nuclear-cytoplasmic transport
through the nuclear pore complex to effectively evade
apoptosis and promote growth [14, 15]. XPO-1-mediated
export is increased in various cancers [16–19]. Examples
of nuclear proteins that are exported into the cytoplasm
in cancer include the drug targets topoisomerase (topo)
IIα [20] and tumor-suppressor proteins such as p53 [21],
p21 [22], and p27 [23]. Use of XPO-1 inhibition in cancer
therapy has been met with limited success. The first stud-
ied XPO-1 inhibitor was the anti-fungal natural antibiotic
leptomycin B. It was found to efficiently inhibit nuclear
export [24], but induced acute toxicities both in vitro [25]
and in a human phase I trial [26]. Other XPO-1 inhibitors
[for review see 14, 15] examined in various studies include
compounds such as ratjadone [27], KOS-2464 [28], FOXO
export inhibitors [29], valtrate [30], acetoxychavicol acetate
[31], CBS9106 [32] and SINE (Selective Inhibitors of Nu-
clear Export) [33–43]. Recent publications have indicated
that SINE compounds may be effective against various
malignancies, including leukemia [34], breast cancer
[35, 36] kidney cancer [37], mantle cell lymphoma [38],
melanoma [39], multiple myeloma (MM) [40], pancreatic
cancer [41], mesotelioma [42] and metastatic PCa [43].
For these reasons, we focused our attention of XPO-1 in-
hibition as therapeutic tool for the treatment of cancer, in-
cluding PCa. In this study, we show that XPO-1 inhibition
using SINE compounds: KPT-185, KPT-205, KPT-225,
and KPT-127 reduced, in a panel of PCa cells, XPO-1-
dependent nuclear export of different proteins including
AR, Foxo3a, and survivin, modulating cell cycle progres-
sion through both a G1 and a G2/M-arrest followed by
apoptosis. Clinical candidate KPT-251 and KPT-330 were
also tested in vivo in three models of aggressive PCa.
Methods
Reagents and drug preparation
All materials for tissue culture were purchased from
Hyclone (Cramlington, NE, USA). Plasticware was ob-
tained from Nunc (Roskilde, Denmark). Antibodies in-
cluding p-GSK3β Ser9 [sc11757], GSK3β [H76, sc-9166],
XPO-1 [sc-5595], P53 [sc126], p-Akt Ser473 [sc-135651],
p-Akt Thr308 [sc135650] and Rad-51 [sc8349], were pur-
chased from Santa Cruz (SantaCruz, CA, USA). Anti-
bodies including CD3 [ab28364], CD68 [ab955], FoxO3a
[ab37409], Iκb [ab32518] were purchased from Abcam
(Cambridge UK). An antibody against Cyclin D1 [#2878]
was purchased from Cell Signaling (Danvers, MA, USA).
A FAS antibody [VP-F702] was purchased from Vector
labs (Burlingame, CA, USA). Ki67 antibody (clone MIB-1)
was purchased from Dako (Dako Italia, Cernusco sul
Naviglio [MI], Italy). Tunel assay kit [S71003] was pur-
chased from Merck KGaA (Darmstadt, Germany). Survi-
vin antibody was purchased from Biorbyt.
SINE compounds (KPT-127, −185, −205, −225, −251,
−330) were provided by Karyopharm Therapeutics Inc.,
Natick, MA. KPT-251 and −330 are suitable for in vivo
use. SINE compounds were dissolved in DMSO and
stored at −20 °C until use.
Human tissues
A cohort of 50 adult patients with clinically localized
PCa, collected as previously described [7]. In addition,
we analyzed 4 lymph nodal metastases from PCa pa-
tients and 57 samples of two tissue arrays from primary
tumors (49 cases) and bone metastases (8 cases) pur-
chased from US Biomax (Rockville, MD, USA). A total
of 121 cases including 99 primary tumors, 4 lymph node
metastases and 8 bone metastases were included. This
research was carried out in accordance with the Helsinki
Declaration and the study was approved by the San
Salvatore Hospital Ethics Committee, L'Aquila, Italy with
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Deliberation n. 89/2006. We obtained also a written in-
formed consent of patients.
Immunohistochemistry
XPO-1 expression was evaluated on 4 μm tissue sections
cut from blocks selected for the presence of representa-
tive tumor tissue. The pathologic evaluation and IHC re-
sults were interpreted by a uro-pathologist. First, nuclear
and cytoplasmic staining of XPO-1 in tumor tissue was
scored blindly (LV) using a semi-quantitative immunore-
activity scoring (IRS) system. Category A scored the in-
tensity of immunostaining as 0 (no immunostaining), 1
(weak immunostaining), 2 (moderate immunostaining),
and 3 (strong immunostaining). Category B scored the
percentage of immunoreactive cells as 0 (none), 1
(<10 %), 2 (10–50 %) and 3 (>50 %). Multiplication of A
and B resulted in an IRS from 0 to 9. An IRS of 4 or
greater was considered high for expression of XPO-1.
This analysis was performed for both nuclear and cyto-
plasmic staining. Global staining (GIRS) was the sum of
nuclear and cytoplasmic staining and ranged between 0
and 18. A GIRS of 8 or greater was considered high for
expression of XPO-1.
Cell lines
Four commercial (LnCaP, 22rv1, DU145 and PC3) and
twelve non-commercial (LAPC-4 [44], CWR22, PCb2
[45], PC3Lymphnode [45], PC3M, PC3M-pro4 [46] and
PC3M-Ln4 [47], LnCaP-104S [47], LnCaP104R1 [47],
LnCaP-C81 [47], C4-2B [48], VCAP [49] and DuCaP
[49) cell lines were selected for the in vitro experimental
studies for their biological characteristics: LAPC-4 (An-
drogen receptor [AR] positive, androgen dependent with
low Akt/mTOR activities, p53 wt); LnCaP (AR positive,
androgen dependent with high Akt/mTOR activities,
p53 wt); LnCaP-C81 and LnCaP-C4-2B (AR positive, an-
drogen independent with high Akt/mTOR activities, p53
wt); 22rv1 (AR positive, androgen independent with low
Akt/mTOR activities, p53 wt); PC3 (AR negative, with
high Akt/mTOR activities and no p53 function (p53 del)
and DU145 (AR negative, with low Akt/mTOR activities
and mutant p53). PC3 and DU145 have been also trans-
fected with AR to obtain PC3AR [50] and DU-AR [51].
Benign prostatic hyperplasia line (BPH1), and Prostatic
epithelial lines (EPN and RWPE-1) were used as non-
neoplastic controls. Cells were routinely cultured in ap-
propriate medium supplemented with 10 % fetal bovine
serum (FBS), 1 % pen-strep and 1 % L-glutamine (Invi-
trogen Corporation, Carlsbad, CA). To minimize the risk
to work with misidentified and/or contaminated cell
lines, DNA profiling was periodically carried out in-
house to authenticate cell cultures. DNA was isolated
from cell lines using a standard DNA isolation kit. STR
profiling was performed by using GenePrint® 10 System
(Promega Corporation, Madison, WI). An eight-capillary
3500 Genetic Analyzer (Applied Biosystems Life Tech-
nologies Europe BV, Monza, Italy) was used to separate
and identify alleles using standard procedures. GenePrint®
10 System allows co-amplification and detection of eight
human loci required by the guidelines ASN-0002. For
non-commercial cell lines, the authentication process was
carried out by comparing STR-fingerprints with those
published by Adri van Bokhoven and co-workers [52]. In
addition, cell lines were stocked at very low passages and
used at <15-20 subcultures.
Growth assays
Cells were seeded at a density of 2 x 104 cells/mL in 24-
well plates. Cells were left to attach and grow in 5 %
FCS DMEM for 24 h. After this time, cells were main-
tained in the appropriate culture conditions. Morpho-
logical controls were performed every day with an
inverted phase-contrast photomicroscope (Nikon Diaphot,
Tokyo, Japan) before cell trypsinization and counting.
Cells were trypsinized and resuspended in 1.0 ml of saline,
then counted using a NucleoCounter™ NC-100 (automated
cell counter systems, Chemotec, Gydevang, Denmark).
The effect on cell proliferation was measured by taking the
mean cell number with respect to controls over time for
the different treatment groups.
Cell viability and apoptosis assay
Viable cells were counted by using the NucleoCounter™
NC-100 (automated cell counter systems, Chemotec,
Cydevang, DK). Apoptosis was evaluated by using Tali®
Apoptosis Kit - Annexin V Alexa Fluor® 488 & Propidium
Iodide-based, (Life Technologies Italia, Monza, Italy).
Stained cells were then measured on a Tali® Image-Based
Cytometer. Apoptosis was further confirmed by FACS
analysis following the instructions of the manufacturer.
Western blot
Cytoplasmic and nuclear protein extracts were obtained
by using the Nuclear/Cytosol Fractionation Kit from
Biovision Inc. (Milpitas, CA, USA). Cell extracts and
conditioned media from treated and untreated cells were
electrophoresed under reducing conditions and trans-
ferred to nitrocellulose filter (Schleicher and Schuell
GmbH, Dassel, Germany). Non specific binding sites
were blocked for 1 h in 5 % non-fat dried milk in a Tris
buffer containing 20 mM Tris and 137 mM NaCl
(pH 7.6). Blots were incubated with 1 μg/ml of primary
antibody diluted in blocking solution for 1 h at room
temperature, washed and then incubated for 1 h in sec-
ondary antibody diluted 1:3000 in blocking solution. Fol-
lowing an additional wash, reactive bands were visualized
by a chemiluminescent detection kit (Supersignal, Perbio






Fig. 1 (See legend on next page.)
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Science, Tattenhall, UK) using Bio-Rad gel Doc™ (Bio-Rad
Laboratories S.r.l., Milan, Italy).
Xenograft model
Male CD1 nude mice (Charles River, Milan, Italy) were
maintained under the guidelines established by the Uni-
versity of L’Aquila, Medical School and Science and
Technology School Board Regulations. Experiments on
animals have been approved by your local IRB in com-
pliance with the Italian government regulation n.116
January 27, 1992 for the use of laboratory animals which
is line with ARRIVE guidelines. All mice received sub-
cutaneous flank injections of 1 x 106 PC3, DU145 or
22v1 cells. Tumor growth was measured bi-weekly with
a Vernier caliper (length x width). Tumor weight was
calculated according to the formula: TW (mg) = tumor
volume (mm3) = d2 x D/2, where d and D are the short-
est and longest diameters, respectively. The effects of
the treatments were examined as previously described
[53]. Animals were sacrificed by carbon dioxide inhal-
ation and tumors were subsequently removed surgically.
A piece of tumor was frozen in liquid nitrogen for pro-
tein analysis and another piece was fixed in paraformal-
dehyde overnight for immunohistochemical analyses.
Martius yellow-brilliant crystal scarlet blue technique
Stains were purchased from HD Supplies (Aylesbury,
UK) and used to analyze the presence of red cells in
tumor tissue and blood vessels, as well as to better
evaluate the presence of micro-thrombi and bleeding
zones. Martius yellow, a small molecule dye, together
with phosphotungstic acid in alcoholic solution stains
red cells. Early fibrin deposits may be colored, but the
phosphotungstic acid blocks the staining of muscle, col-
lagen and connective tissue fibers. Brilliant crystal scar-
let, a medium sized molecule, stains muscle and mature
fibrin. Phosphotungstic acid removes any red stain from
the collagen. The large molecule dye aniline blue stains
the collagen and old fibrin.
Hemoglobin assay
Indirect evaluation of angiogenesis was performed by
using tumor hemoglobin levels as previously described
[53]. Tumors were homogenized in double-distilled water.
Eighty microliters of homogenates were mixed with 1 ml
of Drabkin’s solution and incubated for 15 min at room
temperature. After centrifugation at 400 x g for 5 min, the
supernatants were subjected to absorbance measurement
at 540 nm. The absorption, which is proportional to
hemoglobin concentration, was divided by tumor weight.
Treatments
Mice were treated by oral gavage with either vehicle con-
trol (Pluronic F-68/PVP-K29/32), KPT330 or KPT251. Be-
fore tumor injection, animals were randomized into seven
treatment groups as follows: Group 1: mice (10 animals)
receiving 100 μl vehicle PO; Group 2: mice (10 animals)
receiving 100 mg/kg KPT-251 every two days (Monday
and Friday)/week PO; Group 3: mice (10 animals) receiv-
ing 30 mg/kg KPT-251 every two day/week PO; Group 4:
mice (10 animals) receiving 10 mg/kg/day PO; Group 5:
mice (10 animals) receiving 30 mg/kg KPT-330 every two
days/week PO; Group 6: mice (10 animals) receiving
10 mg/kg KPT-330 every two days/week PO; Group 7:
mice (10 animals) receiving 3 mg/kg/day KPT-330 PO.
Treatments were started when tumor volumes reached
approximately 80 mm3 (Day 0) and were stopped after
28 days. The following parameters were used to quantify
the antitumor effects upon different treatments: (1) tumor
volume measured during and at the end of experiments,
(2) tumor weight measured at the end of experiment, (3)
complete response (CR) defined as the disappearance of
the target lesion with respect to baseline, (4) partial re-
sponse (PR) defined as a reduction of greater than 50 % of
tumor volume with respect to baseline, (5) stable disease
(SD) defined as a reduction of less than 50 % or an in-
crease of less than 100 % of tumor volume with respect to
baseline, (6) tumor progression (TP) defined as an in-
crease of greater than 50 % of tumor volume with respect
to baseline, (7) time to progression (TTP). In vivo,
combinational studies were evaluated by CalcuSyn (Bio-
soft). For the calculation of CI, the values of cell kill for a
fixed tumor volume were considered (determined by the
log cell kill (LCK)). LCK was determined as LCKZ (TKC)/
(3.3KTd), where Td represents the mean control group
doubling time required to reach a fixed tumor volume,
expressed in days, whereas T and C are the same values as
described above [54].
(See figure on previous page.)
Fig. 1 a CRM1 expression in normal prostate gland and BPH (a-c) and PCa of various Gleason score (d-g) and metastases (h, i). Prostate gland
and BPH1 areas expressed very low levels of XPO-1/CRM1 or were negative whereas prostate cancer areas showed different CRM1 expression
both in the cytoplasm and nuclei. Metastatic lesions showed very high stains mainly in the nucleus. b, c statistical evaluation of total (Global
immunoreactivity score), nuclear and cytoplasm XPO-1 expression as indicated in material and methods. d Western blot analyses and densitometric
values (arbitrary/normalized densitometric values, e for XPO-1 expression in some PCa and non neoplastic epithelial cells. f Comparison between XPO-
1 in AR positive (LAPC-4, CWR22, LnCaP, LnCaP-104S, LnCaP-104R1, LnCaP-C81, C4-2B, 22rv1, DuCaP, VCaP, PC3AR and DU145AR) versus AR negative
(PC3 and PC3 variants [PC3PTEN, PC3M-pro4, PC3M-Ln4, PC3Me, PCb2] and DU145) PCa cells lines. g Comparison between androgen-dependent
(LAPC-4, CWR22, LnCaP, LnCaP-104S, DuCaP, VCaP, PC3AR and DU145AR) versus androgen independent/CRPC (LnCaP-104R1, LnCaP-C81, C4-2B, 22rv1,
PC3 and PC3 variants [PC3PTEN, PC3M-pro4, PC3M-Ln4, PC3Me, PCb2] and DU145) PCa cell lines
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Statistical analysis
Continuous variables were summarized as the mean and
SD or 95 % CI for the mean. Statistical comparisons be-
tween controls and treated groups were established by
carrying out the ANOVA test or by Student’s t-test for un-
paired data (for two comparisons). Dichotomous variables
were summarized by absolute and/or relative frequencies.
For dichotomous variables, statistical comparisons be-
tween control and treated groups were established by car-
rying out the exact Fisher’s test. For multiple comparisons,
the level of significance was corrected by multiplying the
P value by the number of comparisons performed (n) ac-
cording to the Bonferroni correction. Overall survival was
determined by Kaplan–Meier analysis and a Gehan's gen-
eralized Wilcoxon test. When more than two survival
curves were compared, the Logrank test for trend was
used. This tests the probability that there is a trend in sur-
vival scores across the groups. All tests were two-sided
and were determined by Monte Carlo significance. P
values <0.05 were considered statistically significant. In
the figures in which statistical analysis was performed, sig-
nificance is indicated by an asterisk. SPSS (statistical ana-
lysis software package, IBM Corp., Armonk, NY, USA)
version 10.0 and StatDirect (version. 2.3.3, StatDirect Ltd,
Altrincham, Manchester, UK) were used for statistical ana-
lysis and graphical presentation.
Results
Expression of XPO-1 in human prostate samples
Prostate tumors were grouped according to the Gleason
score and staging. Bone metastases were also considered.
In Fig. 1a, we show examples for XPO-1 expression in
normal prostate gland, BPH (a-c), PCa of various Gleason
score (d-g) and bone metastases (h-i). Immunoreactivity
was scored as indicated in the materials and methods
section. We observed that the global XPO-1 immune-
reactivity scoring (GIRS) was significantly higher in PCa
(8.35 ± 5.85; cases n = 99) when compared to benign
hypertrophy (BPH; 5.25 ± 1.15; cases n = 38) with p <
0.001 as indicated in Fig. 1b. GIRS values were higher in
Gleason scores > 7 when compared to Gleason scores ≤ 7
both when we considered GIR scores (11.23 ± 5.19 vs
7.47 ± 6.52, P < 0.001) as indicated in Fig. 1c and the per-
centage of patients having high GIR scores (>8) was 36/49
(73.9 %) vs 19/50 (38 %). No differences were observed in
primary tumors from patients with metastatic or non
metastatic tumors. Analyzing the nuclear and cytoplasm
expression levels, we observed a significant increase in
XPO-1 expression in the nucleus in cancer (3.24 ± 3.22)
and BPH (1.33 ± 0.83) with p < 0.01 (Fig. 1b) and in
Gleason scores > 7 when compared to Gleason scores ≤ 7
(5.27 ± 3.24 vs 2.88 ± 3.31, p < 0.001) and 30/49 [61.2 %] vs
16/50 [32 %] cases with high IRS (P < 0.001, Fig. 1c). The
analysis performed on cytoplasm revealed differences be-
tween BPH (3.45 ± 1.07) and PCa (5.61 ± 3.22, P < 0.001,
Fig. 1b) but no significant differences between values of
IRS measured for Gleason scores >7 (5.91 ± 3.20) and ≤ 7
(4.88 ± 3.70, P = 0.086) or the percentage of cases with
high IRS [36/49 (73.5 %) vs 28/50 (56 %)] as shown in
Fig. 1c. Although the mean GIRS values showed no sig-
nificant differences, the percentage of cases with high
XPO-1 expression was significantly higher in primary tis-
sues derived from metastatic compared to those observed
in non metastatic cases. No statistical difference was ob-
served in the comparisons with pathologic stage for nuclear
or cytoplasm IR values. Nevertheless all metastatic lesions
presented elevated GIRS and nuclear IRS for XPO-1.
Expression of XPO-1 in human prostate cancer lines
Next, we analyzed and quantified the expression of
XPO-1 in prostate cancer, normal or neoplastic prostate
epithelial cells by immunoblots and by adjusted densi-
tometry units. XPO-1 protein levels were high in pros-
tate cancer when compared to non neoplastic prostate
epithelial cells (Fig. 1d, e). Statistical analyses reveal that
the XPO-1 expression levels were statistically lower in
AR positive (LAPC-4, CWR22, LnCaP, LnCaP-104S,
LnCaP-104R1, LnCaP-C81, C4-2B, 22rv1, DuCaP, VCaP,
PC3AR and DU145AR) when compared to those observed
in AR negative (PC3 and PC3 variants [PC3PTEN, PC3M-
pro4, PC3M-Ln4, PC3Me, PCb2] and DU145) PCa cells
lines (1.39 ± 0.38 vs 2.57 ± 0.39, P = 0.0015, Fig. 1f). The
XPO-1 levels were statistically lower in androgen depend-
ent (LAPC-4, CWR22, LnCaP, LnCaP-104S, DuCaP, VCaP,
PC3AR and DU145AR) when compared to those observed
in androgen independent/CRPC (LnCaP-104R1, LnCaP-
C81, C4-2B, 22rv1, PC3 and PC3 variants [PC3PTEN,
PC3M-pro4, PC3M-Ln4, PC3Me, PCb2] and DU145) PCa
cell lines (1.41 ± 0.47 vs 2.44 ± 0.52, P = 0.0150, Fig. 1g)
The comparison in PC3 cell derivatives showed higher
XPO-1 levels in more aggressive/metastatic cells.
Inhibition of XPO1 blocks growth of PCa cells
Six SINE analogs KPT-127, KPT-185, KPT-205, KPT-
227, KPT251 and KPT-330 sharing a trifluoromethyl
phenyl triazole scaffold [51, 52], were investigated for
(See figure on previous page.)
Fig. 2 Dose-dependent effects of different KPT compounds in BPH-1, LnCaP (AR+/AD/p53wt), LAPC-4 (AR+/AD/p53mutant), 22rv1(AR+/AI/p53
wt) and PC3 (AR-/p53 null) cells treated with varying doses (0, 1, 10, 50, 100, 500 and 1000 nM) of different KPT compounds and assessed viability
at 72 hours after treatment: KPT-127 (a), KPT-185 (b), KPT-207 (c), KPT-225 (d), KPT-251 (e) and KPT-330 (f). g IC50 for each compound was then
calculated for the wide set of PCa cell lines
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their growth inhibitory and apoptotic potential in our
PCa cell panel. Therefore, the effects of these XPO1 in-
hibitors were evaluated on the growth of PCa cell lines
performing dose- and time-dependent studies. To exam-
ine the dose-dependent effects of these compounds, we
treated cells with varying doses of the compounds (0, 1,
10, 50, 100, 500 and 1000 nM) and assessed viability at
72 hours after treatment. The IC50 for each compound
was then calculated. In Fig. 2a-f we show the growth
curves for LnCAP, LAPC-4, 22rv1 and PC3 cells, expos-
ure to sub-micromolar concentrations of SINE for
72 hrs. In Fig. 2g, we summarized IC50 values calculated
in our cell systems. Most significantly, at the concentra-
tions tested, the SINE showed no effect on growth of
normal or hyperplastic prostate epithelial cells (BPH-1,
RWPE-1 and EPN). We observed that all SINE com-
pounds show good activity in PCa cell lines with IC50
values in the range of 43 and 700 nM. KPT-330, cur-
rently in phase I clinical trials (ClinicalTrials.gov) and
KPT-127 were the most potent growth inhibitors with
IC50 between 43 and 201 nM, whereas the least activity
was observed with KPT-251 (IC50 values ranged between
150 and 300 nM) and KPT-185 (IC50 values ranged be-
tween 180 and 700 nM). Statistical analyses showed a
significant correlation between efficacy of SINE com-
pounds and XPO-1 expression with higher XPO-1 pro-
tein levels being correlated with lower IC50 values (and
thus with higher sensitivity). The better correlation was
found for KPT-127 and KPT-207 (r = −0.728 and −0.717,
P < 0.005), KPT-330 (r = −0.613, P < 0.01) and KPT-251
(r = −0.485, P < 0.05). The effects of SINE compounds
were higher in CRPC when compared to androgen
dependent prostate cancer cell lines. Therefore the mo-
lecular analysis and the in vivo studies were made in
PC3, DU145 and 22rv1 CRPC models.
Molecular changes induced by XPO-1 inhibition
The molecular pathways that are induced by XPO-1 in-
hibition were evaluated by immunoblots, ELISA and im-
munocytochemical analyses performed in PC3, DU145
and 22rv1 as models of CRPC using 100 nM KPT-330
as reference compound. The effects were monitored in
early and chronic treatments. We found that KPT-330
induced an early XPO-1 nuclear accumulation. In paral-
lel, cyclin D1 nuclear expression was increased whereas
cytosolic levels were strongly reduced. However, pro-
longed treatments with KPT-330 dramatically reduced
XPO-1 protein levels. In Fig. 3a, we show representative
western blots for nuclear and cytoplasm expression of
cyclin D1 and XPO-1 in PC3 cell extracts after 2–12 hr
of treatment with KPT-330. In Fig. 3b, we demonstrate
that total XPO-1 levels were also reduced after pro-
longed treatment of PC3 cells with KPT-330. Western
blot and immune-cytochemistry showed similar results.
In addition, prolonged treatment with KPT-330 deter-
mined a reduction of cyclin D1 protein expression in
DU145 cell lines (Fig. 3c). Western analysis demonstrated
a nuclear accumulation of FOXO, p21, p27, cyclin B1 as
shown in Fig. 3d for PC3 cells. Increased nuclear expres-
sion of FOXO3a is visible also by IHC (Fig. 3e) in 22rv1
cells treated with KPT-330. In addition, we found that
KPT-330 treatment increased nuclear expression of p53
and MDM2 (Fig. 3f) and AR (Fig. 3g) in AR+/p53wt
22rv1 cells. Also in this case, prolonged exposure to KPT-
330 significantly reduced the total expression of AR, espe-
cially in the truncated androgen insensitive forms. Indeed,
it has been demonstrated that AR expression is increased
in CRPC and XPO-1 activity is necessary for a completely
functionally active AR-mediated pathway. Therefore, the
inhibition of XPO-1-mediated export machinery may en-
hance AR signaling (manuscript in preparation). In
addition, the disrupted cyclin B1-XPO-1 interactions lead-
ing to a marked nuclear accumulation of cyclin B1 is ne-
cessary for cyclin B1-dependent apoptosis In Fig. 3h, we
demonstrate that proteasome inhibition was able to block
the degradation of XPO-1, Cyclin D1 and survivin redu-
cing the loss of these proteins induced by KPT-330 treat-
ment. Although proteasome inhibitors are considered for
treatment of solid tumors, these compounds could reduce
the effectiveness of selinexor, requiring further investiga-
tion. These molecular changes were associated with accu-
mulation of cells in the G1 cell cycle phase with loss of
cells in the S and G2/M phase (Fig. 4a).
Western blots and ELISAs revealed a reduced nuclear
export of survivin in PCa cell lines after KPT-330 adminis-
tration. In Fig. 4b and c, we show the early reduction of
(See figure on previous page.)
Fig. 3 Molecular arrangements associated to CRM1 inhibition: a-c CRM1 and Cyclin D1 nuclear accumulation. a Western blots for the nuclear
expression of cyclin D1 and CRM1 in PC3 cells treated with 100 nM KPT-330 for 4, 8, 12 and 24 hrs (early events); b Western blots for the cytoplasmic
expression of cyclin D1 and CRM1 in PC3 cells treated with KPT-330 for 24, 48 or 72 hr and and immunocytochemical evaluation for CRM1 in the same
conditions (late events) and c immunocytochemical evaluation for cyclin D1 expression in PC3 cells treated with 100 nM KPT-330 for 8 (T8), 24 (T24)
and 72 (T72) hrs (late events). d Western blots for nuclear expression of Foxo proteins, p21, p27, cyclin E, cdk2, cyclin B1 and Cdk1 in PC3 cells treated
with 100 nM KPT-330 for 2, 4, 8 and 12 hrs (early events). e Immunocytochemical evaluation for Foxo3a expression in 22rv1 cells treated with 100 nM
KPT-330 for 2 (T2), 8 (T8) and 12 (T12) hrs (early events). f Western blots for nuclear expression of p53 and MDM2 in AR+/p53wt 22rv1 cells treated with
100 nM KPT-330 for 4, 8, 12 and 24 hrs (Early events). g Western blot for AR nuclear expression in 22rv1 cells treated with 100 nM KPT-330 for 2, 4, 8
and 12 hr (early events) and h western blot for AR nuclear expression in 22rv1 cells treated with 100 nM KPT-330 for 8 (T8), 24 (T24) and 72 (T72) hrs
(late events). Nuclear expression was normalized to lamin whereas cytosolic expression was normalized to β-actin





Fig. 4 (See legend on next page.)
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cytoplasmic survivin and increase of nuclear accumu-
lation in PC3 cells treated for different times with
100 nM KPT-330. A decrease in cytosolic an increase
in nuclear survivin protein expression was observed
as early as 4 hours after treatment. Survivin contin-
ued to accumulate within the nucleus until 12 hours
after treatment, after which time it decreased dramat-
ically in all cellular compartments.
Immunoblot analysis also showed changes in the Bcl-2
family proteins: Bax, Bcl-2, Bcl-Xl and Bcl-Xs, suggesting
a role in apoptosis (Fig. 4d). This was associated with an
increased caspases-3 dependent PARP cleavage (Fig. 4e-g).
FACS and Histone/DNA ELISA analyses indicated an in-
creased apoptosis. In Fig. 4h we show the dose and time-
dependent apoptosis measured in aggressive PC3, 22rv1,
DU145 and C4-2B cell lines.
XPO-1 inhibition slows prostate tumor growth in vivo
To determine the effects of XPO-1 inhibition on pros-
tate cancer growth in vivo, we used two aggressive
CRPC, PC3, DU145 and 22rv1, cell lines engrafted in
male nude mice. Once tumors were established (80–
100 mm3 in size), mice were divided into seven different
groups (10 mice/group) and treated with varying doses
of KPT-251 (10, 30, 100 mg/kg PO QoDx3) and KPT-
330 (5, 10, 20 mg/kg PO QoDx3). Tumors were mea-
sured for 35 days. The effects of KPT-251 on tumor
growth is shown in Fig. 5 and KPT-330 in Fig. 6. The
mean tumor weight was calculated for each treatment
group. Figure 5 shows that KPT-251 was able to reduce
tumor weight in a dose-dependent manner in PC3 (a-c),
DU145 (d-f) 22rv1 (g-i) xenografts. Statistically significant
differences were observed between the vehicle control
groups and the groups treated with KPT-251 at 10 mg/kg
on Mondays, Wednesdays, and Fridays (P < 0.0001 in
22rv1 and DU145and P = 0.023, in PC3 xenografts), KPT-
251 at 30 mg/kg on Mondays, Wednesdays, and Fridays
(P < 0.0001 in 22rv1 and DU145 and P = 0.002 in PC3
xenografts), and KPT-251 at 100 mg/kg on Mondays,
Wednesdays and Fridays (P < 0.0001 for all xenografts).
ANOVA analysis showed similar statistical significance
(p < 0.0001) in all cell models. In order to reduce the
probability of an error due to the tumor volume at the
start of drug administration we compared the Time to
Progression (TTP) defined as the time (days) necessary to
double the tumor volume for each tumor. The compari-
son of TTP (Fig. 5b, e and h) shows a better behavior of
KPT-251 in 22rv1 and DU145 when compared to the PC3
xenograft in terms of hazard ratio values (Fig. 5c, f and i).
Figure 6 show that KPT-330 was able to reduce tumor
weight in a dose-dependent manner in PC3 (a-c),
DU145 (d-f ) 22rv1 (g-i) xenografts. Statistically signifi-
cant differences were observed between the vehicle con-
trol groups and the groups treated with KPT-330 at
5 mg/kg on Mondays, Wednesdays, and Fridays but not
for DU145 cells (P = 0.014 and P = 0.003, in 22rv1 and
PC3 xenografts, respectively), KPT-330 at 10 mg/kg on
Mondays, Wednesdays, and Fridays (P < 0.001 in all xeno-
grafts), KPT-330 at 30 mg/kg on Mondays, Wednesdays
and Fridays (P < 0.001 in all xenografts). Also in this case,
tumor growth reduction by KPT-330 treatment had a
similar behavior in all cell models and the comparison of
TTP shows improved hazard ratio values of KPT-330 in
22rv1 and DU145 when compared to PC3 xenograft
(Fig. 6c, d). 22rv1 and DU145 cells are more sensitive to
XPO-1 block when compared to PC3 cells. KPT-330 had
better antitumor effects at similar dosage compared to
KPT-251. Histochemical and immunohistochemical anlay-
sis of tumors treated with KPT-251 (100 mg/kg) or KPT-
330 (10 mg/kg showed evidence of cell cycle arrest and
apoptosis after treatment. Sectioned tumors following
42 days of treatment were stained with hematoxylin/eosin,
trichromic stain, Ki-67, TUNEL, CD31, CD68 and Fas.
The results show decreased cell proliferation, seen by
the reduction in the number of Ki-67–positive cells
and increased apoptosis as seen by increase in TUNEL-
positive cells. The reduction in tumor cells can be seen by
the H&E stain as well as with increased fibrosis, as dem-
onstrated by increased trichromic stain (Fig. 7). The in-
duction of Fas suggests that SINE may induce apoptosis
through the activation of the Fas receptors. Increased
staining of CD31 indicates the exposure of blood vessels
in treated shrinking tumors and the increase in CD68 in-
dicated accumulation of monocytes and macrophages in
the areas of the treated tumors (Fig. 7).
Staining of tumor biopsies for XPO1 and selected pro-
tein cargos shows a reduction in total XPO1 protein levels
in treated tumors and increased nuclear localization of
p53, FOXO3 and IκBα (Fig. 8).
Discussion
Multiple tumor suppressor proteins are mislocalized in
cancer cells by overexpressed XPO-1 [13–23]. Here, we
demonstrate that nuclear and cytoplasmic expression of
(See figure on previous page.)
Fig. 4 a Cell cycle evaluation: percentage of cells at different cell cycle phases after treatment with 100 nM KPT-330 at different times (24, 48 and
72 hrs). b-g Molecular arrangements associated to CRM1 inhibition: b, c Survivin nuclear accumulation. Western blot b in PC3 cells treated with
100 nM KPT-330 for 4, 8, 12 and 24 hrs. c ELISA determinations in PC3 cells treated with 100 nM KPT-330 for 4, 8,m 12, 24, 48 and 72; d western
blots for protein associated with apoptosis (Bax and Bcl-2 family members) and caspases. e Activity of caspase 8; f activity of caspase 9.
g Cytofluorimetric analysis of apoptosis
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XPO-1 is elevated in prostate tumors compared to nor-
mal and hyperplastic tissue. In addition, XPO-1 IR is
higher in Gleason score > 7 and metastases, which could
be associated to its function. In vitro aggressive/meta-
static PCa cells show higher levels of XPO-1 when com-
pared to less aggressive cells, and castration resistant
cells show higher XPO-1 levels when compared to an-
drogen dependent cells.
Our results show that SINE compounds, which inhibit
XPO1 activity, have anticancer effects in in vitro and in
vivo models of human cancer. In this report, we also
demonstrate that inhibition of XPO-1 is a potential tar-
get for the treatment of aggressive/castration resistant
PCa. We tested a battery of SINE compounds in PCa
cell lines and KPT-330 and KPT-251 were tested in vivo
using two models of aggressive PCa. The results of our
study demonstrate that SINE compounds are potent an-
ticancer agents in these models. The clinical candidate,
KPT-330, significantly reduced tumor cell growth to ap-
proximately one-third the volume of tumors observed in
docetaxel–treated animals (internal control, data not
shown). Reduction in tumor growth was dose-dependent
and associated with inhibition of cellular proliferation
and activation of apoptosis, which correlated with our in
vitro findings showing PARP and caspase-3 cleavage.
SINE compounds are potent therapeutic tools to treat
aggressive/castration resistant PCa cells. This appears
to be due to the modulation of a multiple signaling
pathways.
It has been demonstrated that cyclin D1 overexpres-
sion increases the progression of PCa [55] and cyclin D1
knockdown reduce cell proliferation and increases sensi-
tivity to radiotherapy and chemotherapy [56]. Cyclin D1
nuclear overexpression induces differentiated phenotype
in B-cell lymphoma in transgenic mice [57] and drives the
oncogenic transformation of murine fibroblasts [58]. Cyc-
lin D1 is sequestered in the cytoplasm of mammalian can-
cer cells [59], where the enforced nuclear localization of
cyclin D1 induces apoptosis. Thus, the subcellular
localization of cyclin D1 may play a role in cell survival.
The competing processes of nuclear import and export in-
duce cyclin D1 localization [60]. Here, we observed that
SINE compounds inhibit cell cycle progression, in-
crease early nuclear expression and reduce late cyclin
D1 expression PCa cells. Cyclin D1 overexpression and
abnormalities in cell-cycle inhibitory genes p21WAF1,
p16INK4a, and p27KIP1 have been reported in PCa
[61]. P21WAF1 mainly localizes to the cytoplasm in
many tumor cells, and cytoplasmic P21WAF1 is anti-
apoptotic. P21WAF1 prevents cell cycle progression at
the G1 phase. KPT-330 and KPT-251 reduce the export of
P21WAF1 from the nucleus and increase nuclear expres-
sion of this protein. This was associated with reduced
Ki67 and increased tunnel staining. Our data is in agree-
ment with those observed by Van der Watt et al., [62]
which found that XPO-1 inhibition significantly reduces
cell proliferation and increases apoptosis and P21 nuclear
localization.
Exogenous and endogenous stress can activate ATM, a
DNA damage sensor that activates the tumor suppressor
p53, which, in turn, inhibits cell cycle progression and
activates DNA repair mechanisms. p53 is often inacti-
vated in PCa due to its deletion or mutation [63]. How-
ever, p53 activity can be also regulated by its subcellular
localization. p53 mis-localization arising from an ab-
errant import mechanism, hyperactive export, or se-
questration with a cytoplasmic factor has been observed
in several cancers. Normally, the nuclear-cytoplasmic
transportation of p53 is tightly regulated. Here, we dem-
onstrated that KPT-330 or KPT-251 are able to block
transport of p53 from the nucleus, leading to its activa-
tion, cell cycle arrest, and apoptosis in p53 wt 22rv1 cells
as previously demonstrated with leptomycin B [24]. Fur-
thermore, down regulation of both p21/Cip1 and p27/
Kip1 produces a more aggressive PCa phenotype [62]. The
nuclear localization of P27KIP1 enables this regulatory
function. However, the nuclear export of P27KIP1 is medi-
ated by the XPO-1 export receptor. Hence, XPO-1 inhib-
ition may restore the negative regulatory function of
P27KIP1 in prostate cell cycle progression.
The constitutive activation of the PI3K pathway is key
to PCa cell survival [9, 10] due to growth factor activation
or phosphatase and tensin homolog (PTEN) loss. In nor-
mal cells, PTEN, the cellular PI3K antagonist, can inhibit
PI3K activation, resulting in the nuclear localization of
Forkhead Box O (FOXO) transcription factors, involved in
multiple signaling pathways and having tumor-suppressor
functions. In PCa deregulation of oncogenic kinases, in-
cluding Akt, extra-signal-regulated kinase, or IκB kinase,
is frequently observed, which may potentially inactivate
(See figure on previous page.)
Fig. 5 KPT-251 inhibits prostate tumor growth in vivo. Once tumors were established (80–100 mm3 in size), mice were divided into four different
groups (10 mice/group) and treated with varying doses of KPT-251 (10, 30, 100 mg/kg Mondays, Wednesdays and Fridays PO). Tumor volumes
were calculated as indicated in MM and followed for 35 days. Group means were calculated and are shown with error bars representing SD for
each group. a Tumor weight of PC3 xenografts treated or not with KPT-251. b Time to Progression (TTP) defined as the time (days) necessary to
double the tumor volume for each tumor, with Kaplan Meyer curves and calculated in DU145 xenografts. c Hazard ratio values. d Determination
of tumor weight in DU145 xenografts treated or not with KPT-251. e Time to Progression (TTP) f Hazard ratio values. g Determination of tumor
weight in 22rv1 xenografts treated or not with KPT251. h Time to Progression (TTP) calculated in 22rv1 xenografts. i Hazard ratio values
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(See figure on previous page.)
Fig. 6 KPT-330 inhibits prostate tumor growth in vivo. Once tumors were established (80–100 mm3 in size), mice were divided into four different
groups (10 mice/group) and treated with varying doses of KPT-251 (5, 10, 20 mg/Kg Mondays, Wednesdays and Fridays PO). Tumor volumes were
calculated as indicated in MM and follow for 35 days. Group means were calculated and are shown with error bars representing SD for each
group. a Tumor weight of PC3 xenografts treated or not with KPT-330. b Time to Progression (TTP) calculated in PC3 xenografts. c Hazard ratio
values. d Determination of tumor weight in DU145 xenografts treated or not with KPT330. e Time to Progression (TTP) calculated in DU145
xenografts. f Hazard ratio values. g Determination of tumor weight in 22rv1 xenografts treated or not with KPT-330. h Time to Progression (TTP)
calculated in 22rv1 xenografts. i Hazard ratio values
Fig. 7 Histochemical and immunohistochemical analyses. Hematoxylin/Eosin and Trichromic staining was shown in PC3 xenografts treated with
KPT-251 (100 mg/kg) and KPT-330 (10 mg/kg). In this panel was also shown the expression of K67, tunnel, CD31, Fas and CD68 staining, depicting
respectively proliferation, apoptosis, vessel formation, cell death receptor and monocyte/macrophage presence
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FOXO activity. FOXO3a is, indeed, in a constant inactive
state due to its cytoplasmic localization. In the nucleus,
FOXO can activate the transcription of genes that pro-
mote cell cycle arrest and apoptosis [64]. Thus, localizing
FOXO to the nucleus is beneficial to controlling cell sur-
vival. The constitutive activation of PI3K constitutively ac-
tivates protein kinase B (AKT) which phosphorylates
FOXO transcription factors at multiple sites, thereby pre-
venting FOXO-DNA binding and transcriptional activ-
ities, as well as promoting the XPO-1-dependent export of
FOXO from the nucleus. We observed that KPT-251 and
KPT-330 significantly induce nuclear localization of
FOXO3a. FOXO re-localization to the nucleus, where it
becomes active, is a promising method of controlling cell
proliferation.
The transcriptional activator nuclear factor-κB (NF-κB)
has been implicated in tumorigenesis and resistance ther-
apy. Advanced/aggressive PCa cells express constitutively
activated NF-κB [65]. Here we observed that IkBα expres-
sion is increased in the nuclei of cells when 22rv1- or
PC3-bearing mice were treated with KPT-330. Therefore,
the perturbation of the XPO-1-dependent nuclear export
of IκBα may attenuate constitutively activated NF-κB and
cause immediate apoptosis in PCa cells.
The Fas/FasL system is significant in tumorigenesis
and a previous investigation has indicated that the im-
pairment of the Fas/FasL system in cancer cells may lead
to apoptosis resistance and contribute to tumor progres-
sion [66]. We observed that KPT-330 and KPT-251 in-
duced the expression of FAS in vitro and in vivo. This
A
B
Fig. 8 a Immunohistochemical evaluation of XPO-1, p53, Foxo3a and IkBa performed in 22rv1 xenografts treated with or without KPT-251 or
KPT-330. In this fig. is shown XPO-1, p53, Foxo3a and IkBa expression to demonstrate the changes in nuclear expression and protein level induced
by KPT-251 (100 mg/kg) and KPT-330 (10 mg/kg) treatments. b Changes in the expression of XPO-1 in PC3 xenografts treated with or without
KPT-251 or KPT-330
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increase could be responsible for the elevation of caspase
8 activity observed in vitro. Therefore FAS/FASL system
could be activated and FASL produced in the tumor
microenvironment by pro-inflammatory and resident
stromal cells could participate to the XPO-1 mediated
cell death. We also observed increased fibrosis and
necrosis associated to increased percentage of CD68
monocytes/macrophages. Taken together these observa-
tions could further increase local FAS/FASL activity. In
addition, it is previously shown that FOXO3A when ac-
tive (nuclear localization) induces the expression of the
FAS ligand protein [67].
High levels of survivin expression are independent risk
factors for poor prognosis in cancer [68]. Cytoplasmic
survivin has been shown to be particularly high in pros-
tate tumors and to be an independent predictor of poor
prognosis, whereas nuclear survivin has been a favorable
factor [68, 69] in some studies. These clinical results
support the notion that nuclear survivin is suppressive
for tumor growth, and further that targeting the cyto-
plasmic, antiapoptotic fraction of survivin would be an
ideal therapeutic avenue. As survivin requires XPO-1/
XPO1-RanGTP for its nuclear exit, inhibiting the activity
of this complex could directly address this therapeutic
need by increasing the tumor-suppressive nuclear survi-
vin and reducing the antiapoptotic cytoplasmic survivin.
Our results suggest that survivin is an essential compo-
nent of the downstream signaling pathway of XPO-1 in-
hibition in prostate cancer cells, intriguingly an increase
in the total concentration of survivin can interfere with
these drugs' antitumor effects. Treatments with KPT-
330 or KPT-251 led to an initial decrease in cytoplasmic
survivin protein levels with a corresponding increase in
its nuclear expression. This result was transient however,
as the major effect was to deplete total survivin levels.
Interestingly, other reports have shown a decrease in
total survivin following treatment with LMB [28], and
more recently it was reported that the NF-κB–dependent
survival factor, Mcl1, is depleted in response to KPT-185
[38]. Taken together, these results provided unequivocal
proof of the potential SINEs as new class of anticancer
drugs. Our results suggest that SINEs initially promote
survivin nuclear localization, but at later time points leads
to a reduction in its protein levels correlating with the
timing of cellular antitumor effects of these com-
pounds and supporting a hypothesis that XPO-1 inhib-
ition leads to a loss of survivin levels which tend to
lead to inhibition of tumor cell growth and enhanced
tumor cell apoptosis.
Conclusions
We demonstrated that the SINE KPT-330, recently dem-
onstrated to inhibit bone metastases formation in PCa
[43] and currently in phase I clinical studies in humans
(NCT01607905), is an interesting therapeutic target for
advanced/castration resistant prostate tumors.
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